ASH Annual Meeting 2024 - Sara Majocchi -

First-in-human trial of NILK-2401, a CEACAM5xCD47 bispecific κλ body

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer

Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody